135575-42-7 Usage
Description
Pneumocandin B0 is an antifungal lipopeptide that acts by inhibiting the synthesis of β-(1,3)-D-glucan, a component of fungal cell walls (IC50s = 70 and 67 ng/ml for inhibiting glucan synthase in C. albicans and A. fumigatus, respectively). It can be used to synthesize the echinocandin caspofungin acetate .
Uses
Different sources of media describe the Uses of 135575-42-7 differently. You can refer to the following data:
1. Pneumocandin B0 is the major analogue of a family of lipopeptides isolated from several species of several different genera, such as Cryptosporiopsis, Glarea and Pezicula. Pneumocandin B0 is a potent antifungal and acts by inhibition of the synthesis of β-(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi.
2. Pneumocandin B0 is the major analogue of a family of lipopeptides isolated from some species of Cryptosporiopsis, Glarea and Pezicula. Pneumocandin B0 is a potent antifungal and acts by inhibiting the synthesis of β-(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi.
Definition
ChEBI: An echinocandin initially isolated as a very minor bioactive fermentation product of Glarea lozoyensis (originally known as Zalerion arboricola). Subsequent random mutagenesis work and optimisation of the fermentation medium permi
ted the industrial production of pneumocandin B0, which is used as the starting point for the synthesis of the antifungal drug caspofungin.
Check Digit Verification of cas no
The CAS Registry Mumber 135575-42-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,5,7 and 5 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 135575-42:
(8*1)+(7*3)+(6*5)+(5*5)+(4*7)+(3*5)+(2*4)+(1*2)=137
137 % 10 = 7
So 135575-42-7 is a valid CAS Registry Number.
InChI:InChI=1/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25?,26?,27-,30+,31-,32-,33-,34-,35+,38-,39-,40-,41-,42-,43-,46+/m0/s1
135575-42-7Relevant articles and documents
Stationary phases and a purification process using the stationary phases
-
Page/Page column 7-8, (2008/06/13)
This invention relates to a novel stationary phase of Formula I and a method for purifying a peptide or lipopeptide in liquid chromatography using select stationary phases, including the stationary phases of Formula I to improve the resolution and/or productivity of the purification. This chromatographic method can be used for either an analytical or preparative scale purification.
